Personalized Management in cSCC

In this final episode, “Personalized Management in cSCC,” the panelists explore how gene expression profiling (GEP) and other molecular tools are advancing precision medicine approaches in cutaneous squamous cell carcinoma (cSCC). The expert faculty discuss how molecular profiling may help refine individualized risk assessment, guide treatment planning, and support more personalized prognostication beyond traditional staging systems alone.

The panel reviews how DecisionDx-SCC results can provide individualized estimates of recurrence and metastatic risk, allowing clinicians and multidisciplinary tumor boards to better tailor recommendations regarding radiation therapy, surveillance, and additional interventions. The expert faculty also discuss ongoing unmet needs in cSCC management, including defining the role of neoadjuvant immunotherapy, optimizing treatment selection for the highest-risk patients, and generating additional evidence to guide future clinical decision-making.

Additionally, the discussion focuses on practical considerations for integrating molecular profiling into everyday dermatology practice. The panelists emphasize the importance of using GEP as an adjunctive clinical tool rather than a replacement for physician judgment and clinical gestalt. The expert faculty highlight the need for thoughtful patient selection, clear communication regarding the strengths and limitations of testing, and close collaboration with multidisciplinary colleagues, including dermatopathologists, radiation oncologists, and medical oncologists.

Throughout the discussion, the panel reinforces the importance of evidence-based medicine, shared decision-making, and multidisciplinary care in advancing more personalized management strategies for patients with cSCC. Thank you for watching this DermView series on cSCC. Please subscribe to our newsletter for information on upcoming video series.